Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Open, Single-arm, Multi-cohort, Multicenter Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer

Next Previous
Trial Profile

A Phase II, Open, Single-arm, Multi-cohort, Multicenter Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Catequentinib (Primary) ; Penpulimab (Primary)
  • Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Lung cancer; Malignant thymoma; Malignant-mesothelioma; Non-small cell lung cancer; Oropharyngeal cancer; Small cell lung cancer; Squamous cell cancer; Thyroid cancer
  • Focus Therapeutic Use
  • Sponsors Chia Tai Tianqing Pharmaceutical Group

Most Recent Events

  • 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
  • 13 Sep 2022 Results (data cutoff date was on Apr 19, 2022, n=12) evaluating the efficacy and safety of anlotinib in combination with penpulimab in patients with pleural mesothelioma or thymic carcinoma who have received at least one line of chemotherapy, presented at the 47th European Society for Medical Oncology Congress
  • 07 Jun 2022 Results from the cohort 1 part of the study for patients with recurrent or metastatic head and neck squamous cell carcinoma, presented at the 58th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top